Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?

被引：25

作者：

Insa, Amelia ^{[1
]}

Martin-Martorell, Paloma ^{[1
]}

Di Liello, Raimondo ^{[2
]}

Fasano, Morena ^{[2
]}

Martini, Giulia ^{[2
]}

Napolitano, Stefania ^{[2
]}

Vicidomini, Giovanni ^{[3
]}

Cappabianca, Salvatore ^{[4
]}

Franco, Renato ^{[5
]}

Morgillo, Floriana ^{[2
]}

Della Corte, Carminia Maria ^{[2
]}

机构：

[1] Hosp Clin Univ Valencia, Med Oncol Dept, Valencia 46010, Spain

[2] Univ Campania Luigi Vanvitelli, Dept Precis Med, Med Oncol, Via Sergio Pansini 5, I-80131 Naples, Italy

[3] Univ Campania Luigi Vanvitelli, Dept Translat Med Sci, Thorac Surg Unit, I-80131 Naples, Italy

[4] Univ Campania Luigi Vanvitelli, Radiol, Dept Precis Med, I-80131 Naples, Italy

[5] Univ Campania Luigi Vanvitelli, Dept Expt Med, Pathol Unit, I-80131 Naples, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2022年 / 169卷

关键词：

Immunotherapy; Chemotherapy; Second line therapy; NSCLC; ICI resistance; CELL LUNG-CANCER; IMMUNE CHECKPOINT INHIBITORS; NIVOLUMAB PLUS IPILIMUMAB; PHASE-III; PD-L1; EXPRESSION; OPEN-LABEL; CHEMOTHERAPY CHEMO; 1ST-LINE NIVOLUMAB; PATIENTS PTS; PEMBROLIZUMAB;

D O I：

10.1016/j.critrevonc.2021.103538

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cancer immunotherapy has produced an unprecedented durable response rate, thus shifting from traditional doublet chemotherapy to immunotherapy-based treatments with and without chemotherapy as the first line strategies for advanced non-small cell lung cancer patients without a molecular driver. However, the majority of patients do not benefit from the treatment or may relapse after a period of response. As few treatment options are available after failure of cancer immunotherapy, including the combination of chemotherapy and antiangiogenic drugs, a better understanding of the mechanisms limiting cancer immunotherapy may be of help in the definition of the best second line. Whereas only retrospective data support an immunotherapy rechallenge approach, new combination strategies including immunotherapy and cell-signaling inhibitors or double immunotherapy represent the newest and most promising strategy to overcome primary or acquired resistance to first line immunotherapy.

引用

页数：10

共 88 条

[11] Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial [J].

Brahmer, Julie R. ;

Rodriguez-Abreu, Delvys ;

Robinson, Andrew G. ;

Hui, Rina ;

Csoszi, Tibor ;

Fulop, Andrea ;

Gottfried, Maya ;

Peled, Nir ;

Tafreshi, Ali ;

Cuffe, Sinead ;

O'Brien, Mary ;

Rao, Suman ;

Hotta, Katsuyuki ;

Zhang, Jin ;

Lubiniecki, Gregory M. ;

Deitz, Anne C. ;

Rangwala, Reshma ;

Reck, Martin .

LANCET ONCOLOGY, 2017, 18 (12) :1600-1609

[12] Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV [J].

Brueckl, Wolfgang M. ;

Reck, Martin ;

Rittmeyer, Achim ;

Kollmeier, Jens ;

Wesseler, Claas ;

Wiest, Gunther H. ;

Christopoulos, Petros ;

Stenzinger, Albrecht ;

Tufman, Amanda ;

Hoffknecht, Petra ;

Ulm, Bernhard ;

Reich, Fabian ;

Ficker, Joachim H. ;

Laack, Eckart .

TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (07) :3093-+

[13] First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer [J].

Carbone, D. P. ;

Reck, M. ;

Paz-Ares, L. ;

Creelan, B. ;

Horn, L. ;

Steins, M. ;

Felip, E. ;

van den Heuvel, M. M. ;

Ciuleanu, T. -E. ;

Badin, F. ;

Ready, N. ;

Hiltermann, T. J. N. ;

Nair, S. ;

Juergens, R. ;

Peters, S. ;

Minenza, E. ;

Wrangle, J. M. ;

Rodriguez-Abreu, D. ;

Borghaei, H. ;

Blumenschein, G. R. ;

Villaruz, L. C. ;

Havel, L. ;

Krejci, J. ;

Corral Jaime, J. ;

Chang, H. ;

Geese, W. J. ;

Bhagavatheeswaran, P. ;

Chen, A. C. ;

Socinski, M. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) :2415-2426

[14] A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer [J].

Cheng, Ning ;

Watkins-Schulz, Rebekah ;

Junkins, Robert D. ;

David, Clement N. ;

Johnson, Brandon M. ;

Montgomery, Stephanie A. ;

Peine, Kevin J. ;

Darr, David B. ;

Yuan, Hong ;

Mckinnon, Karen P. ;

Liu, Qi ;

Miao, Lei ;

Huang, Leaf ;

Bachelder, Eric M. ;

Ainslie, Kristy M. ;

Ting, Jenny P-Y .

JCI INSIGHT, 2018, 3 (22)

[15]

Garassino MC, 2020, J CLIN ONCOL, V38

[16] Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program [J].

Corral, J. ;

Majem, M. ;

Rodriguez-Abreu, D. ;

Carcereny, E. ;

Cortes, A. A. ;

Llorente, M. ;

Lopez Picazo, J. M. ;

Garcia, Y. ;

Domine, M. ;

Lopez Criado, M. P. .

CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (09) :1270-1279

[17] STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype [J].

Della Corte, Carminia M. ;

Sen, Triparna ;

Gay, Carl M. ;

Ramkumar, Kavya ;

Diao, Lixia ;

Cardnell, Robert J. ;

Rodriguez, Bertha Leticia ;

Stewart, C. Allison ;

Papadimitrakopoulou, Vassiliki A. ;

Gibson, Laura ;

Fradette, Jared J. ;

Wang, Qi ;

Fan, Youhong ;

Peng, David H. ;

Negrao, Marcelo V. ;

Wistuba, Ignacio I. ;

Fujimoto, Junya ;

Solis, Luisa M. ;

Behrens, Carmen ;

Skoulidis, Ferdinandos ;

Heymach, John V. ;

Wang, Jing ;

Gibbons, Don L. ;

Byers, Lauren A. .

JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (05) :777-791

[18] Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures [J].

Della Corte, Carminia Maria ;

Barra, Giusi ;

Ciaramella, Vincenza ;

Di Liello, Raimondo ;

Vicidomini, Giovanni ;

Zappavigna, Silvia ;

Luce, Amalia ;

Abate, Marianna ;

Fiorelli, Alfonso ;

Caraglia, Michele ;

Santini, Mario ;

Martinelli, Erika ;

Troiani, Teresa ;

Ciardiello, Fortunato ;

Morgillo, Floriana .

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)

[19] Evading the STING: LKB1 Loss Leads to STING Silencing and Immune Escape in KRAS-Mutant Lung Cancers [J].

Della Corte, Carminia Maria ;

Byers, Lauren Averett .

CANCER DISCOVERY, 2019, 9 (01) :16-18

[20] Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice [J].

Deng, Liufu ;

Liang, Hua ;

Burnette, Byron ;

Beckett, Michael ;

Darga, Thomas ;

Weichselbaum, Ralph R. ;

Fu, Yang-Xin .

JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (02) :687-695

← 1 2 3 4 5 6 7 8 9 →